Otsuka Pharmaceutical - Revision history

Fire: /* Products */

2023-11-21T03:39:24Z

Products

← Older revision		Revision as of 12:39, 21 November 2023
Line 107:		Line 107:
	* [[Wikipedia:Oronamin C\|Oronamin C]]		* [[Wikipedia:Oronamin C\|Oronamin C]]
	* [[Aripiprazole/ja\|Aripiprazole / Abilify]]		* [[Aripiprazole/ja\|Aripiprazole / Abilify]]
			* [[:Category:Nature Made\|Nature Made]]

	==External links==		==External links==

Fire: /* External links */

2023-11-21T03:35:58Z

External links

← Older revision		Revision as of 12:35, 21 November 2023
Line 117:		Line 117:
	{{二次利用\|date=28 October 2023}}		{{二次利用\|date=28 October 2023}}
	[[Category:Otsuka Pharmaceutical\| ]]		[[Category:Otsuka Pharmaceutical\| ]]
	[[Category:~~Companies listed on the Tokyo Stock Exchange]]~~		[[Category:Nature Made]]
	~~[[Category:Pharmaceutical companies of Japan]]~~
	~~[[Category:Food and drink companies of Japan]]~~
	~~[[Category:Pharmaceutical companies established in 1964]]~~
	~~[[Category:Manufacturing companies based in Tokyo]]~~
	~~[[Category:Japanese brands]]~~
	~~[[Category:2010 initial public offerings]]~~
	~~[[Category:Multinational companies headquartered in Japan~~]]

Fire: /* Products */

2023-11-21T03:27:34Z

Products

← Older revision		Revision as of 12:27, 21 November 2023
Line 103:		Line 103:
	==Products==		==Products==
	[[File:Products of Otsuka Pharmaceutical.jpg\|thumb\|Products of Otsuka Pharmaceutical]]		[[File:Products of Otsuka Pharmaceutical.jpg\|thumb\|Products of Otsuka Pharmaceutical]]
	* [[CalorieMate]]		* [[Wikipedia:CalorieMate\|CalorieMate]]
	* [[Pocari Sweat]]		* [[Wikipedia:Pocari Sweat\|Pocari Sweat]]
	* [[Oronamin C]]		* [[Wikipedia:Oronamin C\|Oronamin C]]
	* [[Aripiprazole\|Aripiprazole / Abilify]]		* [[Aripiprazole/ja\|Aripiprazole / Abilify]]


	==External links==		==External links==

Fire: /* Acquisition history */

2023-11-21T03:26:17Z

Acquisition history

← Older revision		Revision as of 12:26, 21 November 2023
Line 86:		Line 86:
	{{Tree list}}		{{Tree list}}
	*'''Otsuka Pharmaceutical Co., Ltd'''		*'''Otsuka Pharmaceutical Co., Ltd'''
	**[[Ridge Vineyards]] <small>(Acq 1986)</small>		**[[Wikipedia:Ridge Vineyards\|Ridge Vineyards]] <small>(Acq 1986)</small>
	**[[Crystal Geyser Water Company]] <small>(Acq 1990)</small>		**[[Wikipedia:Crystal Geyser Water Company\|Crystal Geyser Water Company]] <small>(Acq 1990)</small>
	**[[Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small>		**[[Wikipedia:Astex Pharmaceuticals\|Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small>
	***Astex Therapeutics Limited		***Astex Therapeutics Limited
	***SuperGen, Inc		***SuperGen, Inc
	**[[Avanir Pharmaceuticals]] <small>(Acq 2014)</small>		**[[Wikipedia:Avanir Pharmaceuticals\|Avanir Pharmaceuticals]] <small>(Acq 2014)</small>
	**[[Daiya]] <small>(Acq 2017)</small>		**[[Wikipedia:Daiya\|Daiya]] <small>(Acq 2017)</small>
	**ReCor Medical, Inc. <small>(Acq 2019)</small>		**ReCor Medical, Inc. <small>(Acq 2019)</small>
	**Otsuka America, Inc		**Otsuka America, Inc

Fire: /* Otsuka Pharmaceutical Co. Ltd Holdings */

2023-11-21T03:15:36Z

Otsuka Pharmaceutical Co. Ltd Holdings

← Older revision		Revision as of 12:15, 21 November 2023
Line 60:		Line 60:

	===Otsuka Pharmaceutical Co. Ltd Holdings===		===Otsuka Pharmaceutical Co. Ltd Holdings===
	~~In 1955, the company started a~~ [[football (soccer)\|~~football~~]] ~~club called "Otsuka Pharmaceutical SC." In 2005 the name changed to~~ [[Tokushima Vortis]]~~. The club is based in Naruto.~~		1955年、同社は「大塚製薬SC」という[[:en:football (soccer)\|サッカー]]クラブを立ち上げた。2005年に[[:en:Tokushima Vortis\|徳島ヴォルティス]]と改称した。クラブは鳴門市を本拠地としている。

	~~In 1986, Otsuka Holdings Co. Ltd. acquired~~ [[Ridge Vineyards]].		1986年、大塚ホールディングスが[[:en:Ridge Vineyards\|Ridge Vineyards]]を買収した。

	~~In 1990, Otsuka Holdings Co. Ltd. acquired~~ [[Crystal Geyser Water Company]].		1990年、大塚ホールディングスが[[:en:Crystal Geyser Water Company\|Crystal Geyser Water Company]]を買収した。

	~~In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of~~ [[CG Roxane]].		2008年、大塚製薬株式会社は、[[:en:CG Roxane\|CG Roxane]]の親会社であるAlma S.A.の49%を取得した。

	~~In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with~~ [[UCB (company)\|UCB]] ~~to end collaboration on immunology products while continuing collaboration in the CNS area.~~		2012年初め、大塚製薬は「今後の事業を中枢神経疾患とがん領域に集中する」と発表した。この決定により、[[:en:UCB (company)\|UCB]]との契約条件が変更され、中枢神経系領域での提携は継続する一方、免疫系製品での提携は終了することになった。

	~~In September 2013, Otsuka Holdings it acquired~~ [[Astex\|Astex Pharmaceuticals]] ~~for close to $900 million.~~		2013年9月、大塚ホールディングスは[[:en:Astex\|Astex Pharmaceuticals]]を約9億ドルで買収した。

	~~In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion~~.		2014年12月、大塚ホールディングスはAvanir Pharmaceuticalsを35.4億ドルで買収する契約を締結した。

	~~In March 2017~~, ~~the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug~~ [[centanafadine]] ~~(previously EB~~-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, ~~wholly owned subsidiary.~~		2017年3月にはNeurovanceを2億5,000万ドルで買収することで合意し、同社のフェーズIII段階にあるADHD治療薬[[centanafadine/ja]]（旧名EB-1020）を獲得した。大塚製薬の子会社である大塚アメリカは、Neurovanceに対して1億ドルの契約一時金と、最大1億5,000万ドルの開発・承認マイルストンを支払う。この取引の結果、Neurovanceは間接的な完全子会社として運営されることになる。

	~~In July 2017, the business acquired~~ [[Daiya]].		2017年7月、同事業は[[:en:Daiya\|Daiya]]を買収した。

	~~In July 2018~~, ~~Otsuka agreed to acquire Visterra for $430 million cash and renal-focused ReCor~~ Medical, Inc.		2018年7月、大塚製薬はVisterraを4億3,000万ドルの現金で買収することで合意し、腎臓に特化したReCor Medical, Inc.を買収することに合意した。

	~~In August 2023~~, ~~the company announced its intention to acquire Mindset~~ Pharma Inc ~~for up to CAD$80 million~~.		2023年8月、最大8,000万カナダドルでMindset Pharma Inc.を買収する意向を発表した。

	===Acquisition history===		===Acquisition history===

Fire: /* History */

2023-11-21T03:03:56Z

History

← Older revision		Revision as of 12:03, 21 November 2023
Line 57:		Line 57:

	==History==		==History==
	~~OPC's parent company Otsuka Holdings Co. Ltd. joined the~~ [[~~Tokyo Stock Exchange~~]] ~~through an~~ [[~~initial public offering~~]] ~~(IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader~~ [[Takeda Pharmaceutical Company]]~~. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.~~		OPCの親会社である大塚ホールディングス株式会社は、2010年12月15日に[[:ja:新規株式公開\|新規株式公開]]（IPO）により[[:ja:東京証券取引所\|東京証券取引所]]に上場した。大塚ホールディングスは2010年12月15日に新規株式公開（IPO）を果たし、東京証券取引所に上場した。当時、大塚ホールディングスは売上高で業界トップの[[Takeda Pharmaceutical Company\|武田薬品工業]]に次ぐ国内第2位の薬物メーカーであった。IPOの初値は24億ドルで、それまでの製薬会社としては最大だった。

	===Otsuka Pharmaceutical Co. Ltd Holdings===		===Otsuka Pharmaceutical Co. Ltd Holdings===

Fire at 02:56, 21 November 2023

2023-11-21T02:56:34Z

← Older revision		Revision as of 11:56, 21 November 2023
Line 54:		Line 54:
	\| footnotes =		\| footnotes =
	}}		}}
	{{nihongo\|'''Otsuka Pharmaceutical Co., Ltd.'''\|大塚製薬株式会社\|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo\|4578}})~~, abbreviated '''OPC''', is a~~ [[~~pharmaceutical company~~]] ~~headquartered in~~ [[~~Tokyo~~]], [[~~Osaka~~]] ~~and~~ [[:en:Naruto, Tokushima\|~~Naruto~~]], [[~~Japan~~]]~~. The company was established August 10, 1964.~~		{{nihongo\|'''Otsuka Pharmaceutical Co., Ltd.'''\|大塚製薬株式会社\|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo\|4578}})は、[[:ja:日本\|日本]]の[[:ja:東京\|東京]]、[[:ja:大阪\|大阪]]、[[:en:Naruto, Tokushima\|鳴門]]に本社を置く[[pharmaceutical company/ja\|製薬会社]]である。1964年8月10日に設立された。

	==History==		==History==

Fire at 05:19, 19 November 2023

2023-11-19T05:19:11Z

← Older revision		Revision as of 14:19, 19 November 2023
Line 70:		Line 70:
	In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)\|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.		In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)\|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.

	In September 2013, Otsuka Holdings it acquired [[Astex\|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news\| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905\| title= Japan's Otsuka to buy cancer drug maker Astex Pharma\| author= Tim Kelly\| publisher=Reuters \| date=5 September 2013}}</ref>		In September 2013, Otsuka Holdings it acquired [[Astex\|Astex Pharmaceuticals]] for close to $900 million.

	In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.		In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.

Fire at 05:18, 19 November 2023

2023-11-19T05:18:40Z

← Older revision		Revision as of 14:18, 19 November 2023
Line 11:		Line 11:
	\| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha		\| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha
	\| former_name =		\| former_name =
	\| type = [[Public company\|Public]] [[Kabushiki gaisha\|KK]]		\| type = [[:en:Public company\|Public]] [[:en:Kabushiki gaisha\|KK]]
	\| traded_as = {{TYO\|4578}}<br>[[TOPIX\|TOPIX 100 Component]]		\| traded_as = {{TYO\|4578}}<br>[[TOPIX\|TOPIX 100 Component]]
	\| ISIN =		\| ISIN =
	\| industry = [[Pharmaceutical industry\|Pharmaceutical]]		\| industry = [[Pharmaceutical industry/ja\|Pharmaceutical]]
	\| genre =		\| genre =
	\| fate =		\| fate =
Line 22:		Line 22:
	\| founder = Busaburo Otsuka		\| founder = Busaburo Otsuka
	\| defunct =		\| defunct =
	\| location_city = [[~~Chiyoda, Tokyo~~\|~~Chiyoda~~]], [[~~Tokyo~~]]		\| location_city = [[:ja:東京都\|東京都]][[:ja:千代田区\|千代田区]]
	\| location_country = [[~~Japan~~]]		\| location_country = [[:ja:日本\|日本]]
	\| location =		\| location =
	\| coordinate =		\| coordinate =
	\| locations = 69		\| locations = 69
	\| area_served = Worldwide		\| area_served = Worldwide
	\| key_people = Tatsuo Higuchi <small>([[President (corporate title)\|President]])</small>		\| key_people = Tatsuo Higuchi <small>([[:en:President (corporate title)\|President]])</small>
	\| products =		\| products =
	\| brands =		\| brands =
Line 45:		Line 45:
	\| equity =		\| equity =
	\| equity_year =		\| equity_year =
	\| owner = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''		\| owner = [[Wikipedia:Nomura Trust and Banking\|Nomura Trust and Banking]] [[Wikipedia:investment trusts\|investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
	\| num_employees = 5,634		\| num_employees = 5,634
	\| num_employees_year = 2017		\| num_employees_year = 2017
Line 54:		Line 54:
	\| footnotes =		\| footnotes =
	}}		}}
	{{nihongo\|'''Otsuka Pharmaceutical Co., Ltd.'''\|大塚製薬株式会社\|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo\|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima\|Naruto]], [[Japan]]. The company was established August 10, 1964.		{{nihongo\|'''Otsuka Pharmaceutical Co., Ltd.'''\|大塚製薬株式会社\|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo\|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[:en:Naruto, Tokushima\|Naruto]], [[Japan]]. The company was established August 10, 1964.

	==History==		==History==
	OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].~~<ref name=fujitoslodkowski2010/>~~ The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name=fujitoslodkowski2010>{{Citation \|last1=Fujita \|first1=Junko \|first2=Antoni \|last2=Slodkowski \|editor=Nathan Layne \|date=December 16, 2010 \|publisher=Forexyard \|access-date=January 15, 2012 \|title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 \|type=[[Reuters]] news \|url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 \|url-status=dead \|archive-url=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 \|archive-date=March 4, 2012 }}</ref>		OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]]. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.

	===Otsuka Pharmaceutical Co. Ltd Holdings===		===Otsuka Pharmaceutical Co. Ltd Holdings===
	In 1955, the company started a [[football (soccer)\|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.~~<ref>{{cite web \|title=Tokushima Vortis \|date=15 January 2020 \|url=https://lostinfootballjapan.com/club-profiles/tokushima-vortis/ \|access-date=October 30, 2020}}</ref>~~		In 1955, the company started a [[football (soccer)\|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.

	In 1986, Otsuka Holdings Co. Ltd. acquired [[Ridge Vineyards]].~~<ref>{{cite web \| url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html \| title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 \| Otsuka People Talk }}</ref>~~		In 1986, Otsuka Holdings Co. Ltd. acquired [[Ridge Vineyards]].

	In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]].<ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive\|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf \|date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref>		In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]].

	In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].<ref>{{cite web \|title=Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. \|url=https://www.otsuka.co.jp/en/company/newsreleases/2008/20080528_1.html \|website=otsuka.co.jp \|access-date=October 30, 2020 \|date=May 28, 2008}}</ref>		In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].

	In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref>{{Citation \|date=January 13, 2012 \|publisher=BioSpace \|title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead \|url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 \|access-date=January 15, 2012 \|archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 \|archive-date=March 3, 2016 \|url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)\|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation \|date=January 13, 2012 \|access-date=January 15, 2012\|title=UCB and Otsuka to focus collaboration on CNS disorders \|publisher=Zenopa\|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>		In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)\|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.

	In September 2013, Otsuka Holdings it acquired [[Astex\|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news\| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905\| title= Japan's Otsuka to buy cancer drug maker Astex Pharma\| author= Tim Kelly\| publisher=Reuters \| date=5 September 2013}}</ref>		In September 2013, Otsuka Holdings it acquired [[Astex\|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news\| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905\| title= Japan's Otsuka to buy cancer drug maker Astex Pharma\| author= Tim Kelly\| publisher=Reuters \| date=5 September 2013}}</ref>

	In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.<ref>{{cite web\|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body\|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion\|first=Jonathan\|last=Soble\|website=[[The New York Times]]\|date=2 December 2014 \|access-date=23 April 2018}}</ref>		In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.

	In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web\|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967\|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN\|website=GEN\|date=3 March 2017 \|access-date=23 April 2018}}</ref>		In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.

	In July 2017, the business acquired [[Daiya]].<ref>{{Cite web\|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/\|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka\|website=Food Dive}}</ref>		In July 2017, the business acquired [[Daiya]].

	In July 2018, Otsuka agreed to acquire Visterra for $430 million cash<ref>{{Cite web\|url=https://www.genengnews.com/topics/drug-discovery/otsuka-to-acquire-visterra-for-430m-adding-to-its-pipeline-and-platforms/\|title=Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms\|date=July 11, 2018}}</ref> and renal-focused ReCor Medical, Inc.<ref>{{Cite web\|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/\|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement\|website=BioSpace}}</ref>		In July 2018, Otsuka agreed to acquire Visterra for $430 million cash and renal-focused ReCor Medical, Inc.

	In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.		In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.
Line 106:		Line 106:
	* [[Pocari Sweat]]		* [[Pocari Sweat]]
	* [[Oronamin C]]		* [[Oronamin C]]
	* [[Aripiprazole\|Aripiprazole / Abilify]]<ref>{{cite web \|title=Aripiprazole \|url=http://adisinsight.springer.com/drugs/800001612 \|publisher=AdisInsight \|access-date=4 June 2017}}</ref><ref>{{cite book \|last1=Behere \|first1=Prakash B. \|last2=Das \|first2=Anweshak \|last3=Behere \|first3=Aniruddh P. \|title=Clinical Psychopharmacology: An Update \|date=2018 \|publisher=Springer \|isbn=9789811320927 \|page=66 \|url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref>		* [[Aripiprazole\|Aripiprazole / Abilify]]

	~~==References==~~
	~~{{Reflist}}~~

	==External links==		==External links==

Fire at 05:03, 19 November 2023

2023-11-19T05:03:31Z

← Older revision		Revision as of 14:03, 19 November 2023
Line 1:		Line 1:
	{{Short description\|Japanese pharmaceutical company}}		{{Short description\|Japanese pharmaceutical company}}
	~~{{Expand Japanese\|大塚製薬\|date=March 2020}}~~
	{{Infobox company		{{Infobox company
	\| name = Otsuka Pharmaceutical Co., Ltd.		\| name = Otsuka Pharmaceutical Co., Ltd.